{
    "id": 31773,
    "fullName": "MAP3K1 E864*",
    "impact": "nonsense",
    "proteinEffect": "loss of function - predicted",
    "geneVariantDescriptions": [
        {
            "description": "MAP3K1 E864* results in a premature truncation of the Map3k1 protein at amino acid 864 of 1512 (UniProt.org). Due to the loss of the protein kinase domain (UniProt.org), E864* is predicted to lead to a loss of Map3k1 protein function.",
            "references": [
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 4214,
        "geneSymbol": "MAP3K1",
        "terms": [
            "MAP3K1",
            "MAPKKK1",
            "MEKK",
            "MEKK 1",
            "MEKK1",
            "SRXY6"
        ]
    },
    "variant": "E864*",
    "createDate": "12/12/2019",
    "updateDate": "12/12/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 19523,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a patient-derived xenograft (PDX) model with cutaneous melanoma harboring MAP3K1 E864* demonstrated reduced tumor volume when treated with Mektovi (binimetinib) (PMID: 29795445).",
            "molecularProfile": {
                "id": 34165,
                "profileName": "MAP3K1 E864*"
            },
            "therapy": {
                "id": 807,
                "therapyName": "Binimetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17004,
                    "pubMedId": 29795445,
                    "title": "MAP3K1 and MAP2K4 mutations are associated with sensitivity to MEK inhibitors in multiple cancer models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29795445"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 34165,
            "profileName": "MAP3K1 E864*",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 185900,
            "transcript": "NM_005921",
            "gDna": "chr5:g.56881790G>T",
            "cDna": "c.2590G>T",
            "protein": "p.E864*",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}